Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer

A. Y.C. Chang, A. Solan, B. H. Kaplan, S. E. Vogl, Fernando J. Camacho, S. G. Taylor IV

Research output: Contribution to journalArticle

Abstract

Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity. Adriamycin was given at 40 mg/m2 i.v. and m-AMSA at 50 mg/m2 i.v. every 3 weeks. No response was observed. One patient received an escalated m-AMSA dose at 70 mg/m2 and the same dose of adriamycin. She died of treatment-related leukopenia and infection. We conclude that the combination of adriamycin and amsacrine at the dose and schedule used in our trial has little antitumor effect in the treatment of advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)535-537
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number5
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Amsacrine
Doxorubicin
Breast Neoplasms
Leukopenia
Appointments and Schedules
Therapeutics
Infection

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer. / Chang, A. Y.C.; Solan, A.; Kaplan, B. H.; Vogl, S. E.; Camacho, Fernando J.; Taylor IV, S. G.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 11, No. 5, 01.01.1988, p. 535-537.

Research output: Contribution to journalArticle

Chang, A. Y.C. ; Solan, A. ; Kaplan, B. H. ; Vogl, S. E. ; Camacho, Fernando J. ; Taylor IV, S. G. / Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1988 ; Vol. 11, No. 5. pp. 535-537.
@article{3ff0575985e6488d84199ce0ecdfb530,
title = "Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer",
abstract = "Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity. Adriamycin was given at 40 mg/m2 i.v. and m-AMSA at 50 mg/m2 i.v. every 3 weeks. No response was observed. One patient received an escalated m-AMSA dose at 70 mg/m2 and the same dose of adriamycin. She died of treatment-related leukopenia and infection. We conclude that the combination of adriamycin and amsacrine at the dose and schedule used in our trial has little antitumor effect in the treatment of advanced breast cancer.",
author = "Chang, {A. Y.C.} and A. Solan and Kaplan, {B. H.} and Vogl, {S. E.} and Camacho, {Fernando J.} and {Taylor IV}, {S. G.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1097/00000421-198810000-00005",
language = "English (US)",
volume = "11",
pages = "535--537",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer

AU - Chang, A. Y.C.

AU - Solan, A.

AU - Kaplan, B. H.

AU - Vogl, S. E.

AU - Camacho, Fernando J.

AU - Taylor IV, S. G.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity. Adriamycin was given at 40 mg/m2 i.v. and m-AMSA at 50 mg/m2 i.v. every 3 weeks. No response was observed. One patient received an escalated m-AMSA dose at 70 mg/m2 and the same dose of adriamycin. She died of treatment-related leukopenia and infection. We conclude that the combination of adriamycin and amsacrine at the dose and schedule used in our trial has little antitumor effect in the treatment of advanced breast cancer.

AB - Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity. Adriamycin was given at 40 mg/m2 i.v. and m-AMSA at 50 mg/m2 i.v. every 3 weeks. No response was observed. One patient received an escalated m-AMSA dose at 70 mg/m2 and the same dose of adriamycin. She died of treatment-related leukopenia and infection. We conclude that the combination of adriamycin and amsacrine at the dose and schedule used in our trial has little antitumor effect in the treatment of advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023706675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023706675&partnerID=8YFLogxK

U2 - 10.1097/00000421-198810000-00005

DO - 10.1097/00000421-198810000-00005

M3 - Article

C2 - 3177254

AN - SCOPUS:0023706675

VL - 11

SP - 535

EP - 537

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -